On-Demand Presentations and Slides

Guidelines & Beyond in Colorectal Cancer

Release date 26-11-2020

Expiration date 26-11-2021

The treatment landscape for colorectal cancer (CRC) is changing rapidly, and guidelines for the management of CRC are updated regularly with the aim of assisting clinicians in treatment decision making. View expert faculty presentations, panel discussions, and downloadable slides from the recent live webinar, ‘Guidelines & Beyond in Colorectal Cancer’ which was part of the 2020 Conference of Fudan Zhongshan Cancer Center, and learn about the recent CSCO guidelines update, the challenges around implementing new data in practice, and treatment strategies for patients with metastatic CRC harboring BRAF or HER2 alterations.

Faculty

Gong Chen, MD, PhD

Gong Chen, MD, PhD | Chair

Department of Colorectal Surgery

Sun Yat-sen University Cancer Center

Guangzhou, China

Gong Chen, MD, PhD is the Chief Surgeon and Vice Director at the Department of Colorectal Surgery, Sun Yat-sen University Cancer Center, Guangzhou. He focuses on the surgical and comprehensive treatment of CRC, particularly conversion therapy for CRC liver metastases, total neoadjuvant therapy for low-lying rectal cancer, cytoreductive surgery plus HIPEC for peritoneal carcinomatosis, and neoadjuvant immunotherapy for MSI-H CRC. Dr Chen is a co-investigator for several international multicenter clinical trials. He is first and corresponding author on 30 publications in SCI journals. In addition, he is editor of Chinese versions of N Engl J Med and colorectal Ann Oncol. Dr Chen is the Vice General Secretary for CSCO, a Director of the Colorectal Branch of the Guangdong Anticancer Association, a member of the Standing Committee, Colorectal Surgeon Branch, Chinese Medical Doctor Association, and CSCO’s Expert Committee of GIST, GI NETs, and CRC, and a member of ASCO and ESMO.  

Ying Yuan, MD, PhD

Ying Yuan, MD, PhD

Department of Medical Oncology

The Second Affiliated Hospital
Zhejiang University School of Medicine

Hangzhou, China

Professor Yuan Ying is a Chief Medical Oncologist at The Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang. During her career, she completed 3 years’ postdoctoral training at Lubeck Medical University in Germany and also spent a short period of time at Dana-Farber Cancer Center and Massachusetts General Hospital in Boston, US. Her research focus is the clinical and genetic studies of hereditary colorectal cancer, and personalized and comprehensive treatment of GI and other solid tumors. Currently, Professor Yuan is a Standing Committee Member and leader of the Genetic Group of the Committee of Colorectal Cancer at the Chinese Anti-Cancer Association (CACA), working in a multidisciplinary team (MDT). She is also a Standing Committee Member of the Committee of MDT in the Surgical Branch of the Chinese Medical Doctor Association (CMDA), a Trustee of the CSCO, and a Standing Committee Member and Secretary of the CSCO Committee of Colorectal Cancer.

Alberto Sobrero, MD, PhD

Alberto Sobrero, MD, PhD

Medical Oncology Unit

Ospedale San Martino

Genova, Italy

Professor Alberto Sobrero has been Head of the Medical Oncology Unit at Ospedale San Martino in Genova, Italy, since 2001. Before this, he was Associate Professor in Medical Oncology at the University of Florence. After receiving his medical degree from the University of Genova, he joined Yale University, US, as a Postdoctoral Associate, then a Research Scientist in Medical Oncology. Before returning to Genova, he completed a residency in Internal Medicine at the Yale Affiliated Norwalk Hospital. From 2002–2006, Dr Sobrero was the Chairman of the Protocol Review Committee of EORTC and has been part of the faculty of the ASCO-FECS Clinical Research courses for 7 years. He has been a member of the editorial board of J Clin Oncol, ASCO Scientific Committee, and ESMO Educational Committee, and was Chair of the Scientific Committee of the ESMO Congress in 2017. In 2016, he received the ESMO award. His research interests include GI cancer treatment and design of clinical trials in oncology.

Feng Wang, MD, PhD

Feng Wang, MD, PhD

Department of Medical Oncology

Sun Yat-sen University Cancer Center

Guangzhou, China

Professor Feng Wang is Deputy Director of the Dept. of Medical Oncology at Sun Yat-sen University Cancer Center, Guangzhou. She received her MD from Sun Yat-sen University and PhD from MD Anderson Cancer Center, US. Her research focuses on clinical and biomarker-guided treatment optimization and metabolic regulatory mechanisms in GI cancers. She has published 60 SCI articles including in JAMA Oncol, Cell Res, and Ann Oncol. She has received several awards, including First Prize of Chinese Medical Science & Technology Award and First Prize for Science & Technology Development of the Ministry of Education. She is a Member of the Board Directors of CSCO, Vice Director of the Youth Expert Committee of the Professional Committee of Targeting Therapy of Tumors for the Chinese Anti-Cancer Association, and Director of Youth Expert Committee of the Professional Committee of Targeted and Individualized Therapy in Guangdong Province Anti-Cancer Association. She is a member of ASCO and AACR.

Julien Taïeb, MD, PhD

Julien Taïeb, MD, PhD

Department of Gastroenterology and
GI Oncology

Georges Pompidou European Hospital

Paris, France

Professor Julien Taïeb is the Head of the Gastroenterology and Gastrointestinal Oncology Department at the Georges Pompidou European Hospital, Université de Paris, France. His main research topics are non-metastatic and metastatic colon cancer and pancreatic cancer. He is involved in clinical trials and translational research, has led more than 10 national and international Phase II and III studies, and has authored 3 educational books, more than 300 peer-reviewed publications, and 500 meeting abstracts. He is a regular reviewer for Lancet Oncol, J Clin Oncol, Ann Oncol, Br J Cancer, and the Eur J Cancer. Professor Taïeb is a member of ESMO, ASCO, and a number of French GI cooperative groups and societies. He has a position in the administrative council or the scientific committee of ESMO, Fédération Francophone de Cancérologie Digestive and the Société Nationale Française de Gastro-Entérologie. Additionally, he is the founder of the AGEO French research group on GI tumors.

Hiroya Taniguchi, MD, PhD

Hiroya Taniguchi, MD, PhD

Department of Gastrointestinal Oncology

National Cancer Center Hospital East

Kashiwa, Japan

Dr Hiroya Taniguchi has been a staff doctor at the Department of Gastroenterology and Gastrointestinal Oncology at the National Cancer Center Hospital East, Chiba, Japan, since 2018. Before this, he was a staff doctor in the Department of Clinical Oncology at Aichi Cancer Center Hospital for 6 years. Dr Taniguchi is a member of the Japanese Society of Medical Oncology (JSMO), a board-certified gastroenterologist of the Japanese Society of Gastroenterology (JSGE), a committee member of the GI Group of the West Japan Oncology Group (WJOG), and a guideline committee member of the Japanese Society for Cancer of the Colon and Rectum (JSCCR). He is involved in the clinical and translational research, mainly in colorectal cancer, and is an author, co-author, and contributor of various scientific publications in renowned oncology journals.

Yanhong Deng, MD, PhD

Yanhong Deng, MD, PhD

Department of Medical Oncology

The Sixth Affiliated Hospital of
Sun Yat-sen University

Guangzhou, China

Professor Yanhong Deng is Head of the Cancer Center and Medical Oncology Unit at The Sixth Affiliated Hospital of Sun Yat-Sen University, Guangzhou. She also serves as Director of the Clinical Trial Center and Director of the Drug Clinical Trial Institution. Professor Deng’s main interests are clinical trials in gastrointestinal cancer, and translational research into molecular targeted therapy and immunotherapy.  Dr Deng is a member of the Expert Group of Standards for Diagnosis and Treatment of Colorectal Cancer in China (National Health Commission), Vice President of the Oncology Branch of Chinese Geriatrics Association, Vice Chairman of the Youth Committee of the Colorectal Cancer Professional Committee of the Chinese Anti-Cancer Association, Vice Chairman of the Youth Committee of Colorectal Tumor Branch of Chinese Medical Doctor Association, a member of ASCO and CSCO, and Chair of the Digestive Cancer Committee of Guangdong Women Doctors Association.

  • CSCO colorectal guideline update: Integrating advances into practice | Ying Yuan, MD, PhD

  • Commentary: What are the challenges of implementing new data in practice? | Alberto Sobrero, MD, PhD

  • Clinical case – BRAF-mutant mCRC: Evaluating treatment strategies | Feng Wang, MD, PhD

  • Commentary: What should I do if a patient is BRAF-mutant and MSI-H? | Julien Taïeb, MD, PhD

  • Clinical case – Diagnosis and management of HER2-positive mCRC | Hiroya Taniguchi, MD, PhD

  • Commentary: Challenges in China of managing HER2-positive mCRC | Yanhong Deng, MD, PhD

 

This educational activity is specifically designed for medical oncologists, gastroenterologists, surgical oncologists, and other healthcare professionals involved in the management of colorectal cancer.

 

Upon completion of this educational activity, participants should be able to:

  • Evaluate how the latest advances in the management of early and mCRC impact treatment decision making
  • Determine optimal strategies for patients with BRAF-mutant mCRC
  • Identify when and how to assess HER-2 status in mCRC and treatment strategies

 

Provided by ACE Oncology.

 

This educational activity is supported by an independent grant from the Healthcare business of Merck KGaA, Darmstadt, Germany.

 

This educational activity was part of the 2020 Conference of Fudan Zhongshan Cancer Center.

 

This on-demand webcast includes content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve knowledge, competence, and performance of clinicians in order to improve patient care.

 

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

 

Ying Yuan has no financial relationships to disclose. Any unlabeled/unapproved uses of drugs or products referenced in her presentation will be specified.

 

Alberto Sobrero has served as an advisor or consultant for Merck Serono, Sanofi, Bayer, Servier, BMS, and Amgen. He has served as a speaker or a member of a speakers bureau for Merck Serono, Roche, Sanofi, Bayer, Servier, BMS, and Amgen. Any unlabeled/unapproved uses of drugs or products referenced in his presentation will be specified.

 

Feng Wang has no financial relationships to disclose. Any unlabeled/unapproved uses of drugs or products referenced in her presentation will be specified.

 

Julien Taïeb has served as an advisor or consultant for Amgen, Roche, Merck KGaA, MSD, Lilly, Servier, Sanofi, Pierre Fabre, AstraZeneca, Samsung Bioepis, and HallioDx. He has served as a speaker or a member of a speakers bureau for Amgen, Roche, Merck KGaA, MSD, Lilly, Servier, Sanofi, Pierre Fabre, AstraZeneca, Samsung Bioepis, and HallioDx. Any unlabeled/unapproved uses of drugs or products referenced in his presentation will be specified.

 

Hiroya Taniguchi has received grants for clinical research from Takeda, Sysmex, and Taiho. Any unlabeled/unapproved uses of drugs or products referenced in his presentation will be specified.

 

Yanhong Deng has no financial relationships to disclose. Any unlabeled/unapproved uses of drugs or products referenced in her presentation will be specified.

 

The employees of ACE Oncology have disclosed no relevant financial relationships.

 

ACE Oncology require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COIs are thoroughly vetted and resolved according to ACE Oncology’s policy. ACE Oncology is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

 

Start Activity